Sign In
17 Oct 2011 15:48
For immediate release | 17 October 2011 |
ABCAM PLC
("Abcam" or "the Company")
PDMR dealing
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, was today notified that on 17 October 2011 Ed Ralph, a PDMR of the Company, exercised share options over 12,555 ordinary shares of 0.2 pence each in the Company (Ordinary Shares) at an exercise price of 62.4p per share, and subsequently sold 12,555 shares at a price of 344p per Ordinary Share. On the same day, his wife, Victoria Ralph, also sold 40,000 Ordinary Shares at a price of 344p per share.
Following these transactions, Mr Ralph's total beneficial interest in the Company is 376,756 ordinary shares, representing approximately 0.21 per cent of the current issued share capital of the Company.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer www.abcamplc.com | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.
Abcam now has an online catalogue of over 79,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
Follow the stocks
